The O-Shot After Childbirth and After Menopause: What Changes and What PRP Can Rebuild

Two different women ask about the O-Shot for two completely different reasons. One is eighteen months past a delivery and cannot feel what she used to feel. The other is four years past her last period and finds that everything is drier, thinner, and less forgiving than it was. Both are describing real tissue change. They are not the same tissue change, they do not respond to the same sequence of care, and lumping them together is why so much of what you read about this treatment feels vague.

Want the general overview first? Our complete guide to the O-Shot in Ann Arbor, MI covers what the procedure is, how it is performed, the results timeline, how many sessions are typical, and current pricing. This page is narrower on purpose: it is about what actually changes after childbirth and after menopause, and how the O-Shot fits each one.

Part one: after childbirth

What actually changed

Vaginal delivery stretches, and sometimes tears, tissue that was not designed to be permanently altered but sometimes is. Three things commonly persist well past the six-week check:

• Scar tissue. Whether from a tear or an episiotomy, healed scar is stiffer, less elastic, and less well supplied with blood than the tissue it replaced. It can be tender, or it can be numb, or both in different spots.
• Altered sensation. Stretch injury to small nerves can leave patchy reduced sensitivity that does not track with how well the skin healed. Women describe it as an area that has gone quiet.
• Reduced support around the urethra. This is why stress leakage so often starts after a birth rather than after menopause, and why it can appear in a woman in her thirties who is otherwise in excellent shape.

None of this is a failure of recovery and none of it is fixed by more Kegels once scar quality is the limiting factor. It is a tissue-repair problem, which is exactly the category PRP addresses.

What the research says about postpartum tissue

A systematic review of PRP across pelvic floor disorders analysed fifteen studies covering 600 women and found positive effects across a notably relevant list: perineal trauma and perineal rupture, female sexual dysfunction, vulvovaginal atrophy, stress urinary incontinence, and pelvic organ prolapse. The authors noted that dosing, preparation, and injection technique varied widely between studies and called for standardisation (Kurniawati et al., International Journal of Reproductive Biomedicine, 2024; doi:10.18502/ijrm.v21i12.15034).

Perineal trauma appearing explicitly in that list matters, because it is the postpartum finding most often waved away as "everything healed fine."

Timing after a birth

We do not treat while you are still in active recovery. Give the tissue time to finish its own remodelling and complete your postpartum care first. Beyond that, timing is individual - it depends on how you delivered, whether you tore, whether you are still breastfeeding, and what the tissue looks like on exam. Breastfeeding suppresses estrogen, which affects tissue quality, so that is a genuine part of the conversation rather than a formality. Bring it up and we will plan around it.

The realistic postpartum goal

Better sensation in areas that went quiet, more pliable and less tender scar, and better urethral support if leakage is part of the picture. If bladder leakage is the main issue rather than a side issue, our page on the O-Shot for stress urinary incontinence covers the randomized evidence and how a course is spaced.

Part two: after menopause

What actually changed

The postpartum problem is mechanical. The post-menopausal problem is hormonal, and that difference drives everything about how it is treated.

When estrogen falls, vulvovaginal tissue thins, produces less natural lubrication, loses elasticity, and its blood supply diminishes. The vaginal pH shifts. Sensation dulls because there is less well-perfused tissue to sense with. Intercourse can move from comfortable to uncomfortable to painful. The urethra, which is estrogen-sensitive too, loses support at the same time - which is why dryness and leakage so often arrive as a pair. Collectively this is genitourinary syndrome of menopause, and it is progressive if nothing addresses the underlying hormone loss.

What the research says about post-menopausal tissue

The 2026 systematic review of PRP in the vulvovaginal area covered eighteen studies and 480 patients, 401 treated with PRP. Vulvovaginal atrophy was one of the three most frequent indications studied, with 87 patients, alongside vulvar lichen sclerosus and sexual dysfunction. Across studies, PRP was associated with improvements in symptoms, sexual function, and vaginal health, with few and mild adverse events (De Ponte et al., The Journal of Sexual Medicine, 2026; doi:10.1093/jsxmed/qdaf307).

A separate systematic review looked specifically at injection treatments for vulvovaginal atrophy of menopause across eight studies and 236 women, and found that PRP alone produced significant improvement on the Vaginal Health Index and the Vulvovaginal Symptoms Questionnaire (Moccia et al., Aesthetic Plastic Surgery, 2023; doi:10.1007/s00266-023-03550-5).

There is also direct laboratory evidence for the mechanism in exactly this population. Researchers isolated vaginal fibroblasts from post-menopausal women and cultured them with PRP. The treated cells proliferated more, produced more collagen, shifted from a myofibroblast toward a fibroblast phenotype, and were protected against cellular senescence in long-term culture - findings that held in both two-dimensional and three-dimensional culture systems (Berndt et al., Maturitas, 2025; doi:10.1016/j.maturitas.2025.108196).

Why hormones come first after menopause

This is the single most important thing on this page. PRP delivers a repair signal. Estrogen maintains the tissue that has to act on it. If the tissue is significantly atrophic and estrogen-starved, you are asking a construction crew to build without materials.

So the sequence we use after menopause is usually:

1. Assess and address hormones. A full panel - estradiol, testosterone, DHEA-S, thyroid - interpreted against symptoms rather than in isolation. Local vaginal estrogen where there is atrophy, and systemic support where indicated. Our guides to perimenopause treatment and bioidentical hormone therapy cover the options.
2. Give it eight to twelve weeks. Tissue response lags behind blood levels. A woman whose labs look corrected this month does not have corrected tissue this month.
3. Then the O-Shot. Now the growth factors land in tissue capable of responding, and results tend to be both better and longer-lasting.

Skipping straight to the injection because it sounds faster is the commonest reason women are disappointed by this treatment.

Perimenopause: the overlap zone

Many women arrive somewhere in between - still cycling, but irregularly, with symptoms that started shifting a few years ago. This group often has both mechanical change from earlier births and early hormonal change, and it is the group for whom the combined approach makes the most difference. It is also the group most likely to have been told that what they are describing is normal for their age, which is true and completely unhelpful at the same time.

Frequently asked questions

How long after having a baby can I have the O-Shot?

Not during active postpartum recovery. Beyond that it depends on your delivery, whether you tore, whether you are breastfeeding, and what the exam shows. It is decided individually, not by a fixed number of months.

Can I have it while breastfeeding?

Bring it up at the consultation. Breastfeeding keeps estrogen low, which affects how tissue responds, so it changes the timing conversation and sometimes the sequencing.

Will the O-Shot help post-menopausal dryness on its own?

It can improve vaginal health measures - that is what the atrophy reviews found. But if the dryness is driven by estrogen loss, hormone support is what changes the underlying condition. Best results come from doing both, in that order.

Is it too late if I am years past menopause?

No. Tissue that has been low-estrogen for a long time simply needs the hormonal groundwork laid first, and may benefit from a series rather than a single session. Laboratory work on cells taken from post-menopausal women shows the repair machinery is still responsive.

I have both - a birth years ago and menopause now. Which problem am I treating?

Usually both, and they compound. The assessment separates what is scar and support from what is hormone-driven atrophy, because the plan differs.

Does it help with painful intercourse?

When the pain comes from thin, dry, poorly elastic tissue or from restrictive scar, there is a genuine mechanism for improvement. When it comes from pelvic floor muscle tension, endometriosis, or deep pelvic pathology, the O-Shot is aiming at the wrong tissue and you need a different workup. Our page on who is and is not a good O-Shot candidate walks through how to tell.

Where to start

If you are postpartum, start with an exam of the tissue and an honest description of where sensation changed. If you are post-menopausal, start with hormones, and plan the O-Shot as step two rather than step one. Either way the first appointment is a clinical conversation, and it is genuinely the first time many women have been asked detailed questions about sensation and comfort without being rushed.

Your first visit is $35, applied toward treatment if you proceed. Call or text (734) 436-3357. Arbour Longevity, 2217 Packard St, Suite 15, Ann Arbor, MI 48104, serving Ypsilanti, Saline, Dexter, Chelsea and Washtenaw County. Open Thursday through Monday, 10:00 to 19:00; closed Tuesday and Wednesday. Parking is free and directly outside - no meters, no parking structure. Suite 15 is down a flight of stairs, so call (734) 436-3357 ahead if stairs are difficult for you.

Book your $35 consultation

References

1. Kurniawati EM, Rahmawati NA, Hardianto G, Paraton H, Hadi THS. Role of platelet-rich plasma in pelvic floor disorders: A systematic review. International Journal of Reproductive Biomedicine. 2024;21(12):957-974. PMID 38370486. doi:10.18502/ijrm.v21i12.15034
2. De Ponte A, Cabrera S, Bermúdez Sparice SS, Baulies S, Rodríguez I. Platelet-rich plasma in the management of vulvovaginal disorders: a systematic review. The Journal of Sexual Medicine. 2026;23(1). PMID 41168677. doi:10.1093/jsxmed/qdaf307
3. Moccia F, Pentangelo P, Ceccaroni A, Raffone A, Losco L, Alfano C. Injection Treatments for Vulvovaginal Atrophy of Menopause: A Systematic Review. Aesthetic Plastic Surgery. 2023;47(6):2788-2799. PMID 37580562. doi:10.1007/s00266-023-03550-5
4. Berndt S, Vischer S, Turzi A, Dällenbach P. Optimizing the regenerative potential of vaginal fibroblasts: The role of autologous platelet-rich plasma and hyaluronic acid in vitro. Maturitas. 2025;194:108196. PMID 39842262. doi:10.1016/j.maturitas.2025.108196
5. American College of Obstetricians and Gynecologists. Your Sexual Health. acog.org

This content is educational and does not constitute medical advice. The O-Shot requires clinical evaluation and is not appropriate for everyone. Individual results vary.